| Name | Title | Contact Details |
|---|
Fatima Group is one of the largest business conglomerates in Pakistan operating in diversified sectors like Fertilizers, Textiles, Sugar, Energy, Packaging, Mining & Trading of commodities. Established in 1936 with trading of commodities and gradually entered into the manufacturing of various products. The Group has a success story spread over seven decades, expanding its horizon from trading to manufacturing. With an annual turnover of over 80 billion PKR and more than 6,300 employees, Fatima Group plays an important role in the economic development of the country.
A New Risk Management Architecture - Emerald Bay is an updated solution to solve the problems created in a fractured/dislocated market. We are structured to ensure accountability throughout the life cycle of a risk, driven by integrity of underwriting. Collaborative, Tech Enabled Underwriting - Our technical underwriting and portfolio management is supported by cutting edge technology. We work in partnership with our MGA/PA and reinsurance capital partners to ensure long term sustainability. Partnership: A Full Alignment of Interests - Our approach requires that from producer to carrier to reinsurer all partners are invested in an aligned strategy. Our laser focus is on capital protection so we are there for our insured when they most need us.
Chartered in 1901 as Irondale Bank of Irondale, MO, Unico Bank has thrived under the ownership of Leon and Barbara Brinkley for the past 30 years. Now, Unico Bank has 10 locations in Southeast Missouri and Northeast Arkansas to serve your banking needs. We pay competitive rates on deposit accounts and offer great low rates for loans to fit your needs. Visit any of our banking centers to see how Unico Bank is committed to Everyday Excellence.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Our proprietary software and professional team of CPAs have assisted thousands of businesses retain hundreds of millions of dollars in stimulus funding